Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
7.49
+0.02 (0.27%)
Feb 2, 2026, 1:39 PM EST - Market open
ARCT Employees
As of December 31, 2024, Arcturus Therapeutics Holdings had 176 total employees, including 174 full-time and 2 part-time employees. The number of employees decreased by 4 or -2.22% compared to the previous year.
Employees
176
Change (1Y)
-4
Growth (1Y)
-2.22%
Revenue / Employee
$554,551
Profits / Employee
-$379,028
Market Cap
212.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 176 | -4 | -2.22% | 174 | 2 |
| Dec 31, 2023 | 180 | 10 | 5.88% | 180 | 0 |
| Dec 31, 2022 | 170 | -7 | -3.95% | 170 | 0 |
| Dec 31, 2021 | 177 | 59 | 50.00% | 177 | 0 |
| Dec 31, 2020 | 118 | 30 | 34.09% | 118 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 172 |
| Alector | 156 |
| Silence Therapeutics | 116 |
| Tonix Pharmaceuticals Holding | 81 |
| SAB Biotherapeutics | 63 |
| Achieve Life Sciences | 25 |
| Ovid Therapeutics | 23 |
| Climb Bio | 18 |
ARCT News
- 24 days ago - Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Arcturus Therapeutics to Attend Upcoming Investor Conference - Business Wire
- 2 months ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 3 months ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 3 months ago - Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 - Business Wire
- 3 months ago - Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture - Benzinga
- 3 months ago - Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results - Invezz